Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).
2015 ◽
Vol 33
(15_suppl)
◽
pp. TPS1106-TPS1106
Keyword(s):
Phase 2
◽